Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1130

Camidanlumab

Home » Camidanlumab

Background of Camidanlumab

Camidanlumab is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). Camidanlumab tesirine (Cami-T or ADCT-301) is an antibody-drug conjugate (ADC) composed of a human antibody that binds to the protein CD25, conjugated to a pyrrolobenzodiazepine dimer toxin. The experimental drug, developed by ADC Therapeutics is being tested in clinical trials for the treatment of B-cell Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL), and for the treatment of B-cell acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Specifications

Catalog Number:
KB-1130
Antibody Name:
Camidanlumab
Isotype:
Human IgG1, kappa
FC Muations:
Wild Type
Target:
CD25
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA|FACS|KD
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Collins G, Horwitz S, Hamadani M, Samaniego F, Spira A, Caimi P, Davies A, et al. Analysis of Clinical Determinants Driving Safety and Efficacy of Camidanlumab Tesirine (ADCT301, Cami) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
  2. Spriano F, Tarantelli C, Golino G ,Gaudio E, Scalise L, Cascione L, Zucca E, et al. The Anti-CD25 Antibody-Drug Conjugate Camidanlumab Tesirine (ADCT-301) Presents a Strong Preclinical Activity Both as Single Agent and In Combination in Lymphoma Cell Lines. Presented during the 15th International Conference on Malignant Lymphoma (ICML), held June 18 – 22, 2019, Lugano, Switzerland.